Natural Killer (NK) Cell Transplantation for AML

Completed · Not applicable

Conditions studied: Acute Myeloid Leukemia

In brief

The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.

Key facts

Study ID

NCT00187096

Run by

St. Jude Children's Research Hospital

People needed

49

Starts

2005-09-01

Expected to finish

2013-03-01

Last updated by the study team

2014-06-19

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with AML that is in complete remission, is relapsed or refractory, or with increasing minimal residual disease.
• Participants in complete remission must have recovered from toxicity of previous therapy and have evidence of bone marrow recovery
• Participants who had prior stem cell transplant (SCT) must have no evidence of GVHD and 60 or more days have elapsed since the SCT.

You may not qualify if…

• Participants who are pregnant
• Participants with inadequate renal, liver, or pulmonary functions

Where it is running

• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.